Aquestive Therapeutics, Inc.
AQSTNASDAQHealthcare● Active
$3.91
$-0.02(-0.51%)
Market Cap$388288947
P/E Ratio—
52W High$7.55
52W Low$2.93
Aquestive Therapeutics, Inc. (AQST) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · AQST · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $44.55M | $57.56M | $50.58M | $47.68M | $50.83M |
| Cost of Revenue | $17.15M | $17.87M | $20.83M | $19.39M | $14.99M |
| Gross Profit | $27.39M | $39.69M | $29.75M | $28.29M | $35.84M |
| Gross Margin %(computed) | 61.49% | 68.95% | 58.82% | 59.34% | 70.51% |
| Operating Expenses | |||||
| R&D Expenses | $17.19M | $20.28M | $13.10M | $17.48M | $17.05M |
| G&A Expenses | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Total Operating Expenses | $97.04M | $70.46M | $44.85M | $70.36M | $70.52M |
| Operating Income | ($69.65M) | ($30.77M) | ($15.10M) | ($42.07M) | ($34.68M) |
| Operating Margin %(computed) | -156.36% | -53.46% | -29.86% | -88.23% | -68.22% |
| Interest Income | $0.00M | $3.44M | $16.32M | $0.10M | $0.42M |
| Interest Expense | $17.10M | $16.82M | $7.46M | $12.44M | $22.46M |
| Income Before Tax | ($83.78M) | ($44.15M) | ($7.63M) | ($54.41M) | ($70.54M) |
| Income Tax Expense | $0.00M | ($0.01M) | $0.24M | $0.00M | $0.00M |
| Net Income | ($83.78M) | ($44.14M) | ($7.87M) | ($54.41M) | ($70.54M) |
| Net Margin %(computed) | -188.09% | -76.68% | -15.56% | -114.11% | -138.77% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-0.76 | $-0.51 | $-0.13 | $-1.12 | $-1.85 |
| Wtd Avg Shares | 121.97M | 86.73M | 61.26M | 48.73M | 38.08M |
| EBITDA | ($69.09M) | ($26.62M) | $1.18M | ($39.58M) | ($45.11M) |
| EBITDA Margin %(computed) | -155.10% | -46.24% | 2.34% | -83.01% | -88.75% |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · M
Explore more Aquestive Therapeutics, Inc. data
About Aquestive Therapeutics, Inc. (AQST) Income Statement
Aquestive Therapeutics, Inc. (AQST) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, AQST reported revenue of $0.04B, gross profit of $0.03B (gross margin 61.49%), and net income of ($0.08B) — a net profit margin of -188.09%.
Frequently asked questions
AQST · 4 questionsAquestive Therapeutics, Inc. (AQST) reported revenue of $0.04B for 2025, down 22.6% year-over-year.
AQST revenueAQST salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08